Delivery Order SPE2DB22D3301-SPE2DB26FX4DG
Award Date 10/31/25
Potential Completion Date 11/3/25
Potential Value $8K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order for 420 mg vials of Ontruzant, a trastuzumab biosimilar used in cancer treatment, valued at $11,497.68. Awarded on September 12, 2025, with an ultimate completion date of September 15, 2025, this firm fixed-price contract represents a competitively awarded, non-set-aside delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX)....
- AmerisourceBergen Drug Corp was awarded a delivery order contract on September 22, 2025, by the Defense Logistics Agency Medical Supply Chain to supply one vial of Trodelvy 180mg, a oncology therapeutic medication, for delivery to Conshohocken, Pennsylvania. The contract is a firm fixed price delivery order with a ceiling value of $19,169.16 and an ultimate completion date of September 23, 2025. No set-aside designation was applied to this competitive award, demonstrating AmerisourceBergen's...
- AmerisourceBergen Drug Corp was awarded a delivery order on September 23, 2025, by the Defense Logistics Agency (DLA) to supply 180 mg vials of Trodelvy, a specialty pharmaceutical product used in oncology treatment. The order, valued at $19,169.16 with a firm fixed price structure, is scheduled for completion by October 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive, non-set-aside award...
- The U.S. Defense Department's Medical Supply Chain awarded a $11,764.70 delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Ontruzant 150 mg vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of October 17, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $42,647.60 on August 14, 2025, for the supply of Herceptin 150 mg vials, with a completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with the...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Herceptin 150 mg vials. The $2,650.59 firm fixed-price contract has an ultimate completion date of August 8, 2024. AmerisourceBergen, through its Corporate Office division, will provide these critical oncology medications to support military treatment facilities and other government healthcare programs. This delivery...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 14, 2025, for the supply of Trisenece 40 mg/ml vials, valued at $5,868.59. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is set for ultimate completion on July 15, 2025, with performance occurring at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Ontruzant 420 mg vials, a biosimilar medication used in cancer treatment. This competitively awarded, non-set-aside contract carries a ceiling value of $18,701.64 and is structured as a firm fixed-price delivery order with an ultimate completion date of April 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Ontruzant 150 mg vials with a ceiling value of $9,459.31. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The order is scheduled for ultimate completion by September 30, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $5,748.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ontruzant 420 mg vials, with an ultimate completion date of August 22, 2025. The contract, issued on August 21, 2025, is a non-set-aside award reflecting open competition. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, serving as the prime contractor with no subcontractors identified. This...